Eisai Co., Ltd. (ESALF)
OTC Markets OTCPK · USD · Healthcare · Drug Manufacturers - Specialty & Generic
$30.79 (+0.00%) as of
Key statistics
- Market cap
- 8.69B
- P/E (TTM)
- 33.84
- Forward P/E
- 24.44
- EPS (TTM)
- 0.91
- Dividend yield
- 3.31%
- 52-week range
- 23.88 – 35.00
- Beta
- -0.09
- Revenue (TTM)
- 857.06B
- Profit margin
- 4.94%
- Volume
- 150.00
About Eisai Co., Ltd.
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Tokyo, Japan
- Employees
- 10,543
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.